Antiglaucoma EP2 Agonists: A long road that led somewhere

David F. Woodward; Jenny W. Wang; W. Daniel Stamer; E. Lütjen-Drecoll; Achim H.P. Krauss; Carol B. Toris

doi:10.1089/jop.2019.0041

Antiglaucoma EP₂ Agonists: A long road that led somewhere

David F. Woodward, Jenny W. Wang, W. Daniel Stamer, E. Lütjen-Drecoll, Achim H.P. Krauss, Carol B. Toris

Research output: Contribution to journal › Review article › peer-review

10 Scopus citations

Abstract

For >2 decades, EP₂ agonists have been the subject of antiglaucoma research and development by scientists in industry and academia around the world. The road has led to the recent approval of the first drug of this class. This article reviews the development of EP₂ agonists from conception to clinical approval, discussing pharmacology, structure, biodistribution, therapeutics, and drug delivery. An extensive list of source references is provided for the reader's benefit.

Original language	English (US)
Pages (from-to)	469-474
Number of pages	6
Journal	Journal of Ocular Pharmacology and Therapeutics
Volume	35
Issue number	9
DOIs	https://doi.org/10.1089/jop.2019.0041
State	Published - Nov 2019
Externally published	Yes

Keywords

EP agonists
drug delivery
glaucoma therapy

ASJC Scopus subject areas

Ophthalmology
Pharmacology
Pharmacology (medical)

Access to Document

10.1089/jop.2019.0041

Cite this

@article{c70cb6eb0b6a451e98bf2a7cd17f9055,

title = "Antiglaucoma EP2 Agonists: A long road that led somewhere",

abstract = "For >2 decades, EP2 agonists have been the subject of antiglaucoma research and development by scientists in industry and academia around the world. The road has led to the recent approval of the first drug of this class. This article reviews the development of EP2 agonists from conception to clinical approval, discussing pharmacology, structure, biodistribution, therapeutics, and drug delivery. An extensive list of source references is provided for the reader's benefit.",

keywords = "EP agonists, drug delivery, glaucoma therapy",

author = "Woodward, {David F.} and Wang, {Jenny W.} and Stamer, {W. Daniel} and E. L{\"u}tjen-Drecoll and Krauss, {Achim H.P.} and Toris, {Carol B.}",

year = "2019",

month = nov,

doi = "10.1089/jop.2019.0041",

language = "English (US)",

volume = "35",

pages = "469--474",

journal = "Journal of Ocular Pharmacology and Therapeutics",

issn = "1080-7683",

publisher = "Mary Ann Liebert Inc.",

number = "9",

}

TY - JOUR

T1 - Antiglaucoma EP2 Agonists

T2 - A long road that led somewhere

AU - Woodward, David F.

AU - Wang, Jenny W.

AU - Stamer, W. Daniel

AU - Lütjen-Drecoll, E.

AU - Krauss, Achim H.P.

AU - Toris, Carol B.

PY - 2019/11

Y1 - 2019/11

N2 - For >2 decades, EP2 agonists have been the subject of antiglaucoma research and development by scientists in industry and academia around the world. The road has led to the recent approval of the first drug of this class. This article reviews the development of EP2 agonists from conception to clinical approval, discussing pharmacology, structure, biodistribution, therapeutics, and drug delivery. An extensive list of source references is provided for the reader's benefit.

AB - For >2 decades, EP2 agonists have been the subject of antiglaucoma research and development by scientists in industry and academia around the world. The road has led to the recent approval of the first drug of this class. This article reviews the development of EP2 agonists from conception to clinical approval, discussing pharmacology, structure, biodistribution, therapeutics, and drug delivery. An extensive list of source references is provided for the reader's benefit.

KW - EP agonists

KW - drug delivery

KW - glaucoma therapy

UR - http://www.scopus.com/inward/record.url?scp=85074445049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074445049&partnerID=8YFLogxK

U2 - 10.1089/jop.2019.0041

DO - 10.1089/jop.2019.0041

M3 - Review article

C2 - 31329508

AN - SCOPUS:85074445049

SN - 1080-7683

VL - 35

SP - 469

EP - 474

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

IS - 9

ER -